Inhibition of monocarboxyate transporter 1 by AZD3965 as a novel therapeutic approach for diffuse large B-cell lymphoma and burkitt lymphoma by Noble RA et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International 
License 
 
 
Newcastle University ePrints - eprint.ncl.ac.uk 
 
Noble RA, Bell N, Blair H, Sikka A, Thomas H, Phillips N, Nakjang S, Miwa S, Crossland R, 
Rand V, Televantou D, Long A, Keun HC, Bacon CM, Bomken S, Critchlow SE, Wedge SR.  
Inhibition of monocarboxyate transporter 1 by AZD3965 as a novel therapeutic approach 
for diffuse large B-cell lymphoma and burkitt lymphoma. 
Haematologica 2017, 102(7), 1247-1257. 
Copyright: 
©2017 Ferrata Storti Foundation.  
Material published in Haematologica is covered by copyright. All rights are reserved to the Ferrata Storti 
Foundation. Use of published material is allowed under the following terms and conditions: 
https://creativecommons.org/licenses/by-nc/4.0/legalcode.  
Copies of published material are allowed for personal or internal use. Sharing published material for non-
commercial purposes is subject to the following conditions:  
https://creativecommons.org/licenses/by-nc/4.0/legalcode, sect. 3. 
Reproducing and sharing published material for commercial purposes is not allowed without permission in 
writing from the publisher. 
DOI link to article: 
https://doi.org/10.3324/haematol.2016.163030  
Date deposited:   
11/07/2017 
haematologica | 2017; 102(7) 1247
Received: December 22, 2016. 
Accepted: March 31, 2017.
Pre-published: April 6, 2017.
©2017 Ferrata Storti Foundation
Material published in Haematologica is covered by copyright.
All rights are reserved to the Ferrata Storti Foundation. Use of
published material is allowed under the following terms and
conditions: 
https://creativecommons.org/licenses/by-nc/4.0/legalcode. 
Copies of published material are allowed for personal or inter-
nal use. Sharing published material for non-commercial pur-
poses is subject to the following conditions: 
https://creativecommons.org/licenses/by-nc/4.0/legalcode,
sect. 3. Reproducing and sharing published material for com-
mercial purposes is not allowed without permission in writing
from the publisher.
Correspondence: 
steve.wedge@ncl.ac.uk
Ferrata Storti
Foundation
EUROPEAN
HEMATOLOGY
ASSOCIATION
Haematologica 2017
Volume 102(7):1247-1257
ARTICLENon-Hodgkin Lymphoma
doi:10.3324/haematol.2016.163030
Check the online version for the most updated
information on this article, online supplements,
and information on authorship & disclosures:
www.haematologica.org/content/102/7/1247
Introduction 
The increased reliance on glycolytic metabolism under aerobic conditions, termed
the “Warburg effect”, is adopted by many tumor types and is characterized by an
increased utilization of glucose and a corresponding greater efflux of lactate.1,2
Consequently, there has been much interest in targeting this recognized ‘hallmark
of cancer’ for therapeutic benefit.3,4 One such approach has been to interfere with
lactate transport via inhibition of monocarboxylate transporter (MCT) 1. 
MCT1 and MCT4 are cell membrane-localized, proton-coupled transporters of
Inhibition of monocarboxylate transporter 1 has been proposed as atherapeutic approach to perturb lactate shuttling in tumor cells thatlack monocarboxylate transporter 4. We examined the monocarboxy-
late transporter 1 inhibitor AZD3965, currently in phase I clinical studies,
as a potential therapy for diffuse large B-cell lymphoma and Burkitt lym-
phoma. Whilst extensive monocarboxylate transporter 1 protein was
found in 120 diffuse large B-cell lymphoma and 10 Burkitt lymphoma
patients’ tumors, monocarboxylate transporter 4 protein expression was
undetectable in 73% of the diffuse large B-cell lymphoma samples and
undetectable or negligible in each Burkitt lymphoma sample. AZD3965
treatment led to a rapid accumulation of intracellular lactate in a panel of
lymphoma cell lines with low monocarboxylate transporter 4 protein
expression and potently inhibited their proliferation. Metabolic changes
induced by AZD3965 in lymphoma cells were consistent with a feed-
back inhibition of glycolysis. A profound cytostatic response was also
observed in vivo: daily oral AZD3965 treatment for 24 days inhibited
CA46 Burkitt lymphoma growth by 99%. Continuous exposure of CA46
cells to AZD3965 for 7 weeks in vitro resulted in a greater dependency
upon oxidative phosphorylation. Combining AZD3965 with an inhibitor
of mitochondrial complex I (central to oxidative phosphorylation)
induced significant lymphoma cell death in vitro and reduced CA46 dis-
ease burden in vivo. These data support clinical examination of AZD3965
in Burkitt lymphoma and diffuse large B-cell lymphoma patients with
low tumor monocarboxylate transporter 4 expression and highlight the
potential of combination strategies to optimally target the metabolic
phenotype of tumors.
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ABSTRACT
monocarboxylates such as lactate and pyruvate.5 MCT1 is
expressed widely and possesses a comparatively high
affinity for lactate, allowing it to function as an influx or
efflux transporter depending upon the local lactate con-
centration gradient. In contrast, MCT4 predominantly ful-
fils an efflux transport role in highly glycolytic tissues. The
function of both transporters is dependent upon an associ-
ation with the transmembrane accessory protein CD147
(basigin; BSG) which ensures their correct orientation at
the cell surface.6 MCT1 and MCT4 can be differentially
over-expressed in cancer,7-11 and a subset of tumors express
MCT1 in the absence of appreciable MCT4 protein. In
such cells MCT1 inhibition can have significant conse-
quences: preventing lactate efflux in highly glycolytic
tumor types, and restricting access to lactate in more
oxidative cancer types in which it may be utilized as a res-
piratory fuel.12,13
AZD3965 is an orally bioavailable MCT1 inhibitor,
which is currently under phase I clinical investigation
(NCT01791595).14 Recent studies have demonstrated that
AZD3965 or structurally related MCT1 inhibitors can
inhibit the bidirectional transport of lactate in cancer cells
which lack MCT4 protein and this may inhibit the cells’
growth.7,12,14
We evaluated the metabolic and therapeutic effects of
AZD3965 in aggressive forms of non-Hodgkin lymphoma,
namely, diffuse large B-cell lymphoma (DLBCL) and
Burkitt lymphoma (BL). We demonstrate in patients’ sam-
ples that these diseases often have high MCT1 and unde-
tectable or negligible MCT4 protein expression. We also
show that AZD3965 can inhibit lactate efflux sufficiently
in DLBCL and BL cell lines to alter cellular metabolism and
exert a profound cytostatic effect on lymphoma cell
growth in vitro and in vivo. Finally, we demonstrate that
combining AZD3965 with an inhibitor of oxidative phos-
phorylation (OXPHOS) can induce significant tumor cell
death and reduce lymphoma disease burden in vivo. 
Collectively these studies define a clear opportunity for
the use of AZD3965 in the clinical management of DLBCL
and BL.
Methods 
Information concerning cell origin, authentication, culture
conditions, western blotting and antibody and drug use are
detailed in the Online Supplementary Information. 
Determination of intracellular lactate, protein, cell
growth and viability
Lactate concentration was determined by colorimetric assay
(Trinity Biotech, Co Wicklow, Ireland) and normalized to pro-
tein content. For growth inhibition assays, cells were plated
overnight before treatment for 72 h and assessed using an XTT
assay (Sigma, Saint-Louis, MO, USA). GI50 values were deter-
mined using GraphPad Prism software (version 6). Cell number
and viability were determined concurrently after 72 h and 120 h
of AZD3965 treatment using a hemocytometer and trypan blue
exclusion, respectively.
Immunohistochemistry 
Formalin-fixed, paraffin-embedded, pre-treatment, diagnostic
DLBCL and BL tissue samples were obtained from the
Newcastle Hematology Biobank (National Research Ethics
Service Committee Reference 07/H0906/109+5) and the
Children’s Cancer and Leukaemia Tissue Bank (Reference
08/H0405/22+5), respectively. Immunohistochemistry for
MCT1 and MCT4 was performed on the Ventana Benchmark
(Tucson, AZ, USA) automated immunostaining platform using
Optiview detection. Staining extent and intensity on tumor cells
were evaluated by two hematopathologists (CMB and DT) and
a summary H-score (0-300) calculated as previously described.15
In selected cases, double immunohistochemical staining for
PAX5 (SP34 rabbit monoclonal antibody, Ventana) was used to
distinguish tumor cell versus non-tumor MCT4 expression.
DLBCL cell-of-origin classification was determined by
immunostaining, as described in Culpin et al.,16 using the Hans
algorithm.17
Metabolic assays
Oxygen consumption rate and extracellular acidification rate
were measured using a Seahorse XF24 analyzer (Agilent, Santa
Clara, CA, USA). CA46 or CA46-R cells (2x105) were made to
adhere to Seahorse 24-well plates using Cell-Tak tissue adhesive
(Corning, Wiesbaden, Germany) 1 to 2 h prior to analysis.
To examine intracellular metabolite concentrations, tumor
cells were seeded in media containing dialyzed fetal calf serum
(10%) and treated with dimethlysulfoxide vehicle or AZD3965
(100 nM) for 2 h under normoxic conditions. Following metabo-
lite extraction, liquid chromatography-mass spectrometry analy-
sis was performed as previously described.14
Extracellular metabolites in RPMI supplemented with dia-
lyzed fetal calf serum (10%) were determined using nuclear
magnetic resonance following incubation with AZD3965 (100
nM) for 24 h. The intracellular metabolite composition of tumor
xenograft samples was assessed by gas chromatography-mass
spectrometry. Additional details on metabolic assays are detailed
in the Online Supplementary Information. 
In vivo efficacy of AZD3965 
For in vivo studies, luciferase-expressing CA46 cells18,19 were
injected intravenously, via the tail vein, into NOD/LtSz-scid IL-
2Rγ null (NSG) mice within a laminar flow hood. Mice were
imaged using an IVIS Spectrum pre-clinical imaging system
(Perkin Elmer, Waltham, MA, USA) as previously described.20
IVIS spectrum operators were blinded to treatment assignments.
Both AZD3965 (100 mg/kg, BID) and BAY 87-2243 (9 mg/kg,
QD) or relevant vehicle controls were administered by oral gav-
age. Animal experiments were approved by Institutional Ethical
Review Process Committees and performed under UK Home
Office licenses.
Statistical tests
Statistical significance was examined using a two-tailed
Student t-test, with the exception of group comparisons within
in vivo experiments which were performed using a two-way
ANOVA with a Tukey test, or a Pearson χ2 test to examine
whether post-treatment tumor volumes had decreased relative
to pre-treated volumes. Data comparisons with P-values <0.05
were considered statistically significant.
Results 
Diffuse large B-cell lymphoma and Burkitt lymphoma
are appropriate diseases for AZD3965 treatment 
We re-analyzed MCT1 and MCT4 published gene
expression data from tumor cell lines and found DLBCL
and BL cell lines to be among the lowest expressers of
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MCT4 (SLC16A3) mRNA, particularly in comparison to
those originating from diverse solid tumor types (Online
Supplementary Figure S1).21 In contrast, MCT1 (SLC16A1)
expression was less variable across cancer types. To deter-
mine protein expression in clinical lymphoma samples, we
stained a cohort of 120 DLBCL patients’ samples for both
MCT1 and MCT4 protein and categorized samples using
an immunohistochemical H-score (Online Supplementary
Figure S2). DLBCL samples were found to be negative for
MCT4 (H-Score = 0) in 73% of cases (Figure 1A), despite
variable numbers of MCT4-positive stromal cells identi-
fied by morphology and the absence of a B-cell marker
(PAX5) (data not shown). MCT4 protein staining was absent
in both activated B-cell and germinal center B-cell cell-of-
origin classifications (Figure 1B,C). The majority of sam-
ples had significant tumor cell MCT1 protein expression
which was not significantly associated with MYC translo-
cation status (data not shown). Specimens from ten patients
AZD3965 treatment of lymphoma
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Figure 1. Diffuse large B-cell lymphoma and Burkitt lymphoma are appropriate diseases for AZD3965 treatment. (A) H-score analysis of MCT1 and MCT4 tumor
cell protein expression in 120 samples from DLBCL and 10 BL patient samples. A sample was considered negative (H-score of 0) when no staining was evident on
tumor cells, staining on stromal cells or inflammatory infiltrate being excluded from the analysis. Representative MCT1 and MCT4 immunohistochemical staining
from two DLBCL samples (i and ii) and one BL sample (iii) are shown. (B) Pie charts indicate that the majority of DLBCL samples are MCT4 negative and the relative
proportion of MCT4 negative samples is similar in both activated B-cell (ABC) and germinal center B-cell (GCB) subsets. (C) MCT4 vs.MCT1 H-score plot for the DLBCL
samples in relation to ABC/GCB classification. 
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were also stained and found to have uniformly strong
MCT1 and undetectable MCT4 protein, with the excep-
tion of weak tumor cell staining (H-score ≤ 10) in
inflamed, ulcerated areas within two intestinal BL tumor
samples (Figure 1A). 
That the majority of DLBCL and BL patients’ specimens
examined had little or no evidence of MCT4 protein
expression but appreciable MCT1 suggests that these are
potentially appropriate malignancies in which to examine
MCT1 inhibitor treatment.
AZD3965 induces rapid accumulation of lactate in
human lymphoma cell lines and significantly inhibits
their growth in vitro 
We assembled a panel of DLBCL and BL cell lines and
determined their expression of MCT1 and MCT4 protein
by western blotting (Figure 2A), with confirmatory
immunohistochemistry on a subset (Online Supplementary
Figure S3). The DLBCL cell lines selected included Farage,
OCILY18, Pfeiffer and Toledo, which are representatives of
the germinal center B-cell subtype, and RIVA, an example
of the activated B-cell subtype.22,23 A selection of these cells
have also been characterized according to the Consensus
Cluster Classification, with Farage and OCILY18 being of
the B-cell receptor subtype, and Pfeiffer and Toledo the
OXPHOS subtype.24,25 The BL cell lines examined com-
prised the Epstein-Barr virus-positive Raji and Daudi cells
and Epstein-Barr virus-negative BJAB, BL41, Ramos and
CA46 lines. MCT1 protein expression was detectable in
each lymphoma cell line, all BL cell lines being high
expressers, but more variation being evident in the DLBCL
cell lines, with RIVA being a high expresser, Toledo, Pfeiffer
and OCILY18 being intermediate expressers and Farage a
comparatively low expresser (Figure 2A). 
With the exception of BJAB, all cell lines were found to
be negative for MCT4 and, consistent with such cells
being reliant on MCT1 for lactate transport, they accumu-
lated lactate intracellularly (>25 μg/mg protein, P<0.05)
following AZD3965 treatment (Figure 2B). Notably, nei-
ther the absolute concentration of lactate attained follow-
ing AZD3965 treatment nor the magnitude of accumula-
tion relative to basal control conditions (i.e. fold change)
correlated with MCT1 protein expression. In contrast, the
MCT4-positive BJAB cell line did not show a significant
change in intracellular lactate following MCT1 inhibition
(P=0.16). An examination of the time-dependency of lac-
tate accumulation in CA46 cells, revealed a rapid increase
in intracellular lactate within the first 30 min following
treatment with 100 or 1000 nM of AZD3965 (Figure 2C).
While a reduction (of 40-50%) from peak lactate levels
was observed by 24 h, a concentration of approximately
50 μg of lactate per mg of protein was largely maintained
between 24 and 72 h (Figure 2C) suggesting attainment of
an intracellular lactate equilibrium. Although maximal lac-
tate accumulation was not evident until 6 h following
incubation with 10 nM of AZD3965, the lactate concen-
tration at 24 and 72 h was comparable to that achieved
with 100 nM and 1000 nM AZD3965 treatment (Figure
2C). However, a concentration of 100 nM AZD3965 was
chosen for all further single concentration experiments,
given the more rapid onset of lactate accumulation.
AZD3965 potently inhibited the proliferation of DLBCL
and BL cell lines in which lactate accumulation was
observed (Figure 2D-F; 72 h GI50 values ranged from 3 to
39 nM). However, proliferation of the MCT4-expressing
cell line BJAB was not markedly reduced (Figure 2D),
<10% growth inhibition being evident following exposure
to 10 μM AZD3965 (n=3; data not shown). Although
AZD3965 induced a profound cytostatic effect in DLBCL
and BL cells without MCT4, limited effects on cell viabili-
ty were detected over a 72 h period (Figure 2G,H).
Furthermore, when incubation with a >GI95 (72 h data)
concentration of AZD3965 was prolonged to 120 h, only
a modest loss of cell viability in Raji (23%) and a <5%
change in CA46 viability (Figure 2I) were detectable.
Consequences of AZD3965 treatment on tumor 
cell metabolism and efficacy in an in vivo Burkitt 
lymphoma model
We examined the consequences of AZD3965 treatment
(2 h incubation) on cellular metabolism in three DLBCL
and two BL cell lines in vitro. MCT1 inhibition increased
the intracellular levels of tricarboxylic acid cycle (TCA)
intermediates across a number of the AZD3965-sensitive
cell lines (Figure 3A; Online Supplementary Figure S4),
potentially reflecting increased activity of the TCA cycle.
We also observed changes in the glycolytic pathway,
including lactate accumulation and increased levels of
early glycolytic intermediates, in particular glucose-6-
phosphate, consistent with lactate inducing feedback inhi-
bition of phosphofructokinase.26 The reduction in fruc-
tose-bisphosphate observed in CA46 and Daudi cells,
would also be predicted to reduce pyruvate kinase activity
and contribute to reduced glycolytic flux. To determine
whether these effects could be reproduced in vivo, we
grew CA46 BL cells subcutaneously in NSG mice and har-
vested tumors 2 h after mice had been given a single oral
dose of AZD3965 (100 mg/kg). Tumor lactate accumula-
tion was evidenced by both biochemical assay (Figure 3B)
and gas chromatography – mass spectrometry analysis
(Figure 3C). Reductions in glutamate and succinate were
also observed in tumors (Figure 3C). 
Given that intracellular tumor lactate was elevated by
AZD3965 treatment, we next sought to determine the
consequences of this on CA46 growth in vivo. CA46 tumor
cells, engineered to ectopically express firefly luciferase,
were inoculated intravenously and their growth deter-
mined by bioluminescence in vivo imaging.  Cell engraft-
ment was confirmed 6 days after inoculation, prior to
commencing oral treatment with AZD3965 or vehicle.
AZD3965 treatment for 24 days inhibited tumor growth
by 99% (Figure 3D,E). Reduced CA46 cell engraftment in
AZD3965-treated animals was also evident from a lack of
human CD20 staining in spleen (Figure 3F,G) and preser-
vation of normal spleen weight. Evidence of CD20 stain-
ing was found in only 8% (1/13) of femora recovered from
AZD3965-treated mice, whereas engraftment was
observed in 86% (12/14) of vehicle-treated mice (Figure
3G and data not shown).
Adaptive resistance to AZD3965 in vitro involves 
a greater dependency on oxidative phosphorylation
To determine whether an adaptive resistance to
AZD3965 could be induced in vitro, CA46 cells were cul-
tured continuously in the presence of 10 nM of the com-
pound for 4 weeks followed by 100 nM for 3 weeks. This
resulted in cells with reduced sensitivity to the anti-prolif-
erative effects of the compound (termed CA46-R cells)
(Figure 4A). Significant AZD3965-induced intracellular lac-
tate accumulation was observed in both CA46 and CA46-
AZD3965 treatment of lymphoma
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Figure 2. MCT1 inhibition induces rapid accumulation of lactate and significant anti-proliferative activity in diffuse large B-cell lymphoma and Burkitt lymphoma
cell lines. (A) MCT1 and MCT4 protein expression in cell lines using GAPDH as a loading control. (B) Intracellular lactate in cell lines following 24 h incubation with
AZD3965 (1 μM) or vehicle. (C) Concentration and time dependency of intracellular lactate accumulation in CA46 cells following treatment with AZD3965 or vehicle.
(D-F) Sensitivity of BL or DLBCL cells treated with AZD3965 for 72 h assessed by XTT assay. (G and H) Cell number and viability following AZD3965 (100 nM) treat-
ment for 72 h. (I) Cell viability following an extended 120 h exposure to AZD3965 (100 nM). Graphs show the means of ≥3 independent experiments ± SEM.
*P<0.05, **P<0.01, ***P<0.001 by unpaired two-tailed t-test.
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Figure 3. AZD3965 alters cellular metabolism in vitro and in vivo causing growth inhibition. (A) Levels of tricarboxylic acid (TCA) cycle and glycolytic intermediates
in cell lines following 2 h exposure to AZD3965 (100 nM) determined by liquid chromatography-mass spectrometry. Significantly altered metabolites (P<0.05) are
expressed as log2 fold-change relative to vehicle-treated control. αKG: alpha-ketoglutarate; FBP: fructose-bisphosphate; F1P: fructose-1-phosphate; F6P: fructose-6-
phosphate; GAP: glyceraldehyde-3-phosphate; G1P: glucose-1-phosphate; G6P: glucose-6-phosphate. (B) NSG mice with subcutaneous CA46 xenografts were treat-
ed with AZD3965 (100 mg/kg) or vehicle and tumors collected after 2 h. Lactate concentrations were normalized to protein. (C) Significantly altered (unpaired two-
tailed t-test) intra-tumoral metabolite levels determined by gas chromatography-mass spectrometry. (D) NSG mice were inoculated intravenously with luciferase-
expressing CA46 cells and 6 days later (treatment day 0) treated with AZD3965 (100 mg/kg, BID) or vehicle for 24 days. Representative images from two mice in
the AZD3965 and vehicle-treated groups using different radiance scales (p/sec/cm2/sr) for mice prior to treatment and during treatment to avoid image saturation.
(E) Mean total flux from AZD3965 and vehicle-treated mice (n=8 per group). (F) Spleen weights from AZD3965 and vehicle-treated mice. Reference historical spleen
weights from NSG mice were 0.02–0.05 g.19 (G) Immunohistochemical analysis of CA46 infiltration via anti-CD20 staining of bone marrow and spleen sections from
mice treated with AZD3965 or vehicle. Statistical significance was assessed by an unpaired two-tailed t-test *P<0.05, ***P<0.001. 
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R cells and, although the concentration of lactate in CA46-
R was 28% less than in the parental cell line, the level
attained was comparable to or greater than that achieved
in other AZD3965-sensitive lines following drug treat-
ment, including Daudi, Toledo, and Pfeiffer cells. There
was no evidence of MCT4 being expressed as a potential
compensatory mechanism to mediate lactate efflux (Figure
4B). In contrast, the levels of MCT1 and its co-chaperone
CD147 were lower in CA46-R cells, suggesting that the
level of functional MCT1 may be reduced (Figure 4B). The
doubling times of CA46 and CA46-R were comparable
(Online Supplementary Figure S5A) and resistance was main-
Figure 4. Acquired resistance to
AZD3965 in vitro is associated with
increased oxidative metabolism. (A)
The sensitivity of CA46 and CA46-R
cells to AZD3965 (72 h treatment)
determined by an XTT assay and cell
counting. (B) Intracellular accumulation
of lactate determined after 24 h expo-
sure to AZD3965 (1 μM). MCT1, MCT4
and CD147 protein levels assessed by
western blotting. (C) Extracellular acidi-
fication rate (ECAR) in CA46 and CA46-
R with and without treatment with
AZD3965 (100 nM) or vehicle. Oxygen
consumption rate (OCR) in CA46 and
CA46-R cells, indicating the effects fol-
lowing addition of oligomycin, FCCP and
antimycin. ECAR and OCR values (mean
± SEM) are normalized to protein
expression and representative of three
independent experiments.
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tained following culture in drug-free medium for 2 weeks
(data not shown). To explore an altered metabolic pheno-
type, the relative consumption and release of metabolic
substrates was assessed following 24 h of AZD3965 treat-
ment. CA46-R showed increased glutamine uptake,
decreased lactate release and increased pyruvate export
(Online Supplementary Figure S5B), changes consistent with
reduced glycolytic lactate production and increased glu-
cose and glutamine oxidation with which to fuel TCA
cycle activity.
We also examined the respective contributions of gly-
colysis and OXPHOS in CA46 and CA46-R cells. Acute
exposure to AZD3965 triggered a rapid decrease in extra-
cellular acidification rate in CA46 cells but not in CA46-R
cells which demonstrated a lower basal extracellular acid-
ification rate (Figure 4C). CA46 and CA46-R differed
markedly in their basal oxygen consumption rate, with
CA46-R utilizing more oxygen (Figure 4C). Collectively,
these measurements are indicative of CA46-R cells having
a more oxidative metabolic phenotype (additional details
are available in the Online Supplementary Information). 
Combining AZD3965 with inhibitors of complex I 
triggers cell death 
Since inhibition of glycolysis will generate greater
reliance on OXPHOS for ATP generation, simultaneous
inhibition of mitochondrial complex I may trigger cell
death,12 a phenomenon demonstrated in Raji cells by com-
bining AZD3965 with metformin (Figure 5A). However,
the concentrations of metformin required to demonstrate
this effect were significantly in excess of those that can be
achieved in mice following oral dosing.27 We therefore
examined the potent complex I inhibitor BAY 87-2243,
which would subsequently permit inhibition of OXPHOS
to be studied in mice.28 While the BL cell lines, Raji and
CA46 were insensitive to BAY 87-2243 monotherapy in
vitro, the combination of AZD3965 with BAY 87-2243
induced profound cell death in both cell lines (Figure
5B,C). CA46-R cells were more sensitive to the growth
inhibitory effect of BAY 87-2243 than parental CA46 cells,
but a combination of BAY 87-2243 and AZD3965 was
similarly required to induce cell death (Figure 5D). In con-
trast, cell death was not evident when AZD3965 was
combined with BAY 87-2243 in MCT4 protein-expressing
BJAB cells (data not shown).
Combining AZD3965 with BAY 87-2243 in vivo
To examine MCT1 inhibition combined with complex
I inhibition in vivo, mice were inoculated intravenously
with luciferase-expressing CA46 cells (Figure 6A). Mean
tumor engraftment was equivalent 12 days after inocula-
tion (P>0.05 for all group comparisons by two-way
ANOVA; Figure 6B), prior to dosing. Following treatment
(72 h after the last dose) mice were re-imaged and
AZD3965 monotherapy treatment again resulted in sig-
nificant control of tumor growth, mean tumor volume
being not significantly different from pre-treatment val-
ues (Figure 6B; P>0.05 by the two-tailed t-test). While
tumor burden in control or BAY 87-2243-treated animals
had increased markedly from each pre-treatment value,
the combination of AZD3965 with BAY 87-2243 led to a
reduction in mean tumor burden compared with the pre-
treated value in four of five mice, with signal intensities
being reduced by between 10- to 267-fold (Figure 6B;
P=0.01 by the Pearson χ2 test). This is consistent with the
induction of lymphoma cell death in vivo. The combina-
tion treatment regimen was well tolerated with no signif-
icant differences in body weight when compared to that
in the control vehicle-treated group throughout treat-
ment (data not shown). All tumor inhibitory effects were
lost upon cessation of treatment as engraftment pro-
gressed in each drug-treated group, indicating that target-
ing of metabolism is likely to require continuous therapy
(Figure 6C).
Discussion
This study aimed to evaluate DLBCL and BL as potential
tumor types appropriate for the clinical development of
AZD3965, a novel MCT1 inhibitor currently undergoing
phase I evaluation.
Although a glycolytic phenotype and increased genera-
tion of lactate are implicated in the pathogenesis of both
DLBCL and BL, the relative expression of MCT1 versus
MCT4 in DLBCL has been less clear. A previous study
examining clinical gene expression data confirmed high
expression of MCT1 mRNA and low expression of MCT4
mRNA in BL but suggested that the converse was true in
a cohort of non-Hodgkin lymphomas that would have
contained predominantly DLBCL samples.12 Our examina-
tion of MCT1 and MCT4 protein using immunohisto-
chemistry showed uniformly strong MCT1 staining in BL
with a corresponding lack of MCT4. However, our analy-
sis also indicated that the majority of DLBCL does not
stain positive for MCT4 protein. DLBCL samples without
MCT4 protein expression were observed among both cell-
of-origin subgroups, and in groups with and without any
MYC aberration. This suggests that all major DLBCL sub-
groups contain patients with an MCT1-positive/MCT4-
negative protein expression profile, who may be appropri-
ate candidates to receive AZD3965 treatment.
Additional experiments examining neuroblastoma cell
lines (IMR-32 and SH-SY5Y; Online Supplementary Figure
S6) and a previous study on small cell lung cancer cells7
demonstrated that only partial sensitivity to AZD3965 can
be observed in solid tumor cell lines lacking MCT4 expres-
sion, despite significant lactate accumulation. Solid tumor
cell lines also have a much broader spectrum of MCT4
mRNA expression in comparison to those of hematologic
origin (Online Supplementary Figure S1). Although these
data do not exclude AZD3965 as being suitable for the
treatment of a subset of solid tumors, the more potent GI50
and uniform response to AZD3965 treatment observed in
DLBCL and BL cell lines suggest that these B-cell malig-
nancies are better disease indications in which to initially
examine the clinical activity of AZD3965. 
Importantly, MCT1 protein expression per se does not
clearly correlate with the extent of lactate accumulation or
growth inhibition observed in vitro following AZD3965
treatment. Prospective stratification of patients for
AZD3965 treatment should prioritize the treatment of
patients whose tumors do not stain positive for MCT4 pro-
tein, rather than treatment based upon the magnitude of
MCT1 protein expression. The lack of effect of AZD3965
on both intracellular lactate concentration and growth of
the MCT4-expressing BJAB lymphoma cell line is consis-
tent with previous data showing that MCT4 overexpres-
sion in a breast cancer cell line or RAS-transformed fibrob-
lasts confers resistance to MCT1 inhibitor treatment.12,29
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The effect of inhibiting MCT1 in DLBCL and BL cell
lines in vitro was predominantly cytostatic. Encouragingly,
however, we also observed a striking cytostatic response
in vivowith AZD3965 treatment, which halted progressive
splenic engraftment of the lymphoma. The incidence of
BL is increased in elderly patients and the median age of
diagnosis for DLBCL is around 70 years.30,31 Given that not
all of these patients will be fit enough to tolerate multi-
agent chemo-immunotherapy, a well-tolerated oral cyto-
static therapy could have significant clinical utility in this
group of patients or in individuals who have relapsed fol-
lowing current standard-of-care treatment.
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Figure 5. Combining AZD3965 with inhibitors of
mitochondrial complex I induces death of Burkitt
lymphoma cells. Viable cell numbers were deter-
mined by cell counting with trypan blue exclusion
over a 72 h period, following treatment with
AZD3965, a complex I inhibitor, or the combination.
(A) Raji cells treated with vehicle, AZD3965 (100
nM), metformin (1 mM) or the combination. (B) Raji
cells treated with vehicle, AZD3965 (5 nM), BAY 87-
2243 (100 nM) or the combination. (C) CA46 and
(D) CA46-R cells treated with vehicle, AZD3965 (10
nM), BAY 87-2243 (10 nM) or the combination. All
graphs show the means of ≥3 independent experi-
ments ± SEM. 
A B
C
D
The compensatory metabolic alterations observed after
AZD3965 treatment in vitro, following either acute or
chronic exposure, support an adaptive metabolic response
that causes a greater reliance on OXPHOS and increased
TCA activity. In order to elicit tumor cell death, when tar-
geting the glycolytic tumor phenotype it may be necessary
to inhibit multiple metabolic pathways, or nodes in a
given pathway, ensuring that there is a basis for tumor
selectivity with at least one of the approaches used. Our
data confirm that a combination of AZD3965 with differ-
ent complex I inhibitors induces rapid cell death in BL
(Figure 5A-D) and DLBCL (data not shown) cell lines in vitro.
We also verified that such a combination can reduce CA46
disease burden in vivo, in contrast to the cytostatic effect
induced by administration of AZD3965 alone.
Approaches to induce tumor cell death and impart cura-
tive activity would be particularly desirable in the treat-
ment of children, in whom BL accounts for the majority of
non-Hodgkin lymphoma.32
Collectively, the striking activity of AZD3965 monother-
apy observed in DLBCL and BL cell lines, and its potential
for use in combination, provides a rationale for examining
the efficacy of this agent against these malignancies.
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signal intensity subsequent to treatment. Graph
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